Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,874 | -8,123 | -6,130 | -3,945 | -1,704 |
| Depreciation Amortization | 8 | 129 | 102 | 73 | 40 |
| Accounts payable and accrued liabilities | -167 | 81 | 126 | 242 | 133 |
| Other Working Capital | -736 | -340 | 65 | -37 | -370 |
| Other Operating Activity | 382 | 1,659 | 926 | 458 | 40 |
| Operating Cash Flow | $-2,387 | $-6,594 | $-4,911 | $-3,210 | $-1,861 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -51 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-51 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 6,912 | 745 | N/A | N/A |
| Other Financing Activity | 0 | 3,872 | 3,872 | 3,872 | 0 |
| Financing Cash Flow | $N/A | $10,784 | $4,617 | $3,872 | $N/A |
| Beginning Cash Position | 7,273 | 3,083 | 3,083 | 3,083 | 3,083 |
| End Cash Position | 4,835 | 7,273 | 2,789 | 3,745 | 1,222 |
| Net Cash Flow | $-2,438 | $4,190 | $-294 | $662 | $-1,861 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,387 | -6,594 | -4,911 | -3,210 | -1,861 |
| Capital Expenditure | -51 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -2,438 | -6,594 | -4,911 | -3,210 | -1,861 |